Comparative pharmacokinetics of naringin and neohesperidin after oral administration of flavonoid glycosides from Aurantii Fructus Immaturus in normal and gastrointestinal motility disorders mice
| Autor: | Ning Xie, Chun-zhen Wu, Chun-hong Jiang, Si-yang Fan, Ren-jie Yan, Zhi-ru Xu |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Pharmacology
Naringenin Neohesperidin Cmax food and beverages Absorption (skin) 030226 pharmacology & pharmacy 01 natural sciences 0104 chemical sciences 010404 medicinal & biomolecular chemistry 03 medical and health sciences chemistry.chemical_compound Atropine 0302 clinical medicine Complementary and alternative medicine Pharmacokinetics chemistry Oral administration medicine Pharmacology (medical) Naringin medicine.drug |
| Zdroj: | Chinese Herbal Medicines. 11:314-320 |
| ISSN: | 1674-6384 |
| DOI: | 10.1016/j.chmed.2019.03.011 |
| Popis: | Objective To compare the pharmacokinetics of naringin and neohesperidin after oral administration of Zhishi total flavonoid glycosides (ZSTFG) extracted from Aurantii Fructus Immaturus in normal and gastrointestinal motility disorders (GMD) mice. Methods ZSTFG was orally given to normal and GMD mice induced by atropine or dopamine. The plasma samples were incubated with β-glucuronidase/sulfatase, the total (free + conjugated) naringenin and hesperitin were extracted with acetonitrile. The validated HPLC-MS/MS method was successfully applied to the pharmacokinetic study. Results The results showed that, compared with the normal group, AUC0–∞, AUC0–t and Cmax for total naringenin and hesperitin were significantly higher (P Conclusion The results showed that there were significant differences in pharmacokinetic parameters of naringenin and hesperitin between normal and GMD groups. It was suggested that the absorption of naringenin and hesperitin was increased, and the elimination processes of naringenin and hesperitin were slower in the GMD group than the normal group. The data are of value for further pharmacological studies of ZSTFG and would be useful to provide a reference for improving the therapeutic regimen of ZSTFG in clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect